ARA-290 (Cibinetide)
Neuropathy · By Preptide Pro editorial team · Last updated
ARA-290 (Cibinetide) is a neuropathy peptide, and it is not FDA-approved. A peptide derived from erythropoietin that does not stimulate red blood cell production. Studied in small clinical trials for neuropathic pain.
Not FDA-approvedChemistry (PubChem)
| PubChem CID | 91810664 |
|---|---|
| CAS number | 1208243-50-8 |
| Molecular formula | C51H84N16O21 |
| Molecular weight | 1257.3 g/mol |
| Other names | Cibinetide, ARA290, PHBSP, PH-BSP, ARA-290, ARA 290, pHBSP peptide, Cibinetida |
Is ARA-290 (Cibinetide) FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on ARA-290 (Cibinetide)?
PubMed lists 86 records for “cibinetide OR ARA-290 OR ARA290”, of which 5 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. | Front Oral Health | 2026 |
| Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management. | Curr Pain Headache Rep | 2026 Aug 24 |
| Pharmacological Management of Diabetic Neuropathy: Current Evidence, Clinical Positioning, and Emerging Therapeutic Targets. | Curr Neuropharmacol | 2026 Aug 22 |
| Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice. | Neurobiol Dis | 2026 Jun 1 |
| Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy. | Front Neurol | 2025 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.